Penn Researchers Build ApexGO, Lifting 72% of AI-Designed Antibiotic Variants

2 articles · Updated · The Daily Pennsylvanian · Jun 15

ApexGO, a new University of Pennsylvania AI model, not only flags antimicrobial peptides but also proposes stronger versions, with 72% of generated variants outperforming their template molecules in bacteria-killing tests.
In lab validation, 85% of synthesized molecules created by the system killed bacteria, and some peptides later tested in mice showed stronger inhibitory activity than certain FDA-approved last-resort antibiotics.
The model narrows a vast peptide search space by learning sequence patterns and balancing promising candidates with uncertain ones, helping researchers avoid largely random wet-lab screening.
Penn researchers framed the work as a response to antimicrobial resistance, which they said is linked to 5 million deaths a year and could reach 10 million annually by 2050 without new treatments.

Sources

The Daily Pennsylvanian4d ago

Penn Researchers Develop ApexGO AI Model for Enhanced Antibiotic Discovery

News-Medical.Net4d ago

AI discovers hidden antibiotic candidates inside disease-causing prions

How soon could AI-generated antibiotics be ready for human trials to combat the growing superbug crisis?

Will AI solve the biggest challenge: turning promising lab discoveries into stable, effective, and affordable medicines for patients?

ApexGO and the Global AMR Crisis: AI-Driven Antibiotic Discovery to Prevent 10 Million Deaths per Year

Overview

Antimicrobial resistance (AMR) is a growing global health crisis, projected to cause up to 10 million deaths annually by 2050, with Asia and Africa facing the highest tolls. This urgent threat highlights the need for innovative solutions, as current antibiotics are becoming less effective and there are major gaps in the development of new treatments. ApexGO, an advanced AI-powered tool, has emerged to address this challenge by rapidly optimizing antibiotic candidates and accelerating drug discovery. Its development marks a significant step forward in combating AMR and strengthening the pipeline for new antimicrobial agents.

...